FR2182914A1 - - Google Patents

Info

Publication number
FR2182914A1
FR2182914A1 FR7311419A FR7311419A FR2182914A1 FR 2182914 A1 FR2182914 A1 FR 2182914A1 FR 7311419 A FR7311419 A FR 7311419A FR 7311419 A FR7311419 A FR 7311419A FR 2182914 A1 FR2182914 A1 FR 2182914A1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7311419A
Other versions
FR2182914B1 (fr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyorin Pharmaceutical Co Ltd
Original Assignee
Kyorin Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyorin Pharmaceutical Co Ltd filed Critical Kyorin Pharmaceutical Co Ltd
Publication of FR2182914A1 publication Critical patent/FR2182914A1/fr
Application granted granted Critical
Publication of FR2182914B1 publication Critical patent/FR2182914B1/fr
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
FR7311419A 1972-03-30 1973-03-29 Expired FR2182914B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP47032033A JPS5229318B2 (fr) 1972-03-30 1972-03-30

Publications (2)

Publication Number Publication Date
FR2182914A1 true FR2182914A1 (fr) 1973-12-14
FR2182914B1 FR2182914B1 (fr) 1976-05-14

Family

ID=12347544

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7311419A Expired FR2182914B1 (fr) 1972-03-30 1973-03-29

Country Status (12)

Country Link
US (1) US3850941A (fr)
JP (1) JPS5229318B2 (fr)
AR (1) AR197709A1 (fr)
BE (1) BE797554A (fr)
BR (1) BR7302268D0 (fr)
CA (1) CA989843A (fr)
DE (1) DE2315801C3 (fr)
ES (1) ES413188A1 (fr)
FR (1) FR2182914B1 (fr)
GB (1) GB1378375A (fr)
HU (1) HU167305B (fr)
SE (1) SE402592B (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2289192A1 (fr) * 1974-11-01 1976-05-28 Kyorin Seiyaku Kk Pyrazolo(1,5-a)pyridines et medicament contenant ces substances
EP0215438A2 (fr) * 1985-09-14 1987-03-25 Kyorin Seiyaku Kabushiki Kaisha Utilisation de la 3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine pour préparer un médicament antirhumatismal
EP0319902A3 (en) * 1987-12-10 1990-01-31 Kyorin Seiyaku Kabushiki Kaisha Transdermal absorptive drug formulation
EP0355234A1 (fr) * 1988-08-25 1990-02-28 Merrell Dow Pharmaceuticals Inc. Dérivés de la pyrazolo-pyridine avec activité antiethérosclérotique et hypecholesthérolémique

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4097483A (en) * 1974-11-01 1978-06-27 Kyorin Pharmaceutical Co., Ltd. Pyrazolo 1,5-a!pyridines
US4237300A (en) * 1975-12-09 1980-12-02 Merck & Co., Inc. Certain 6-substituted-2-pyridinamines
JPS5968553A (ja) * 1982-10-13 1984-04-18 Automob Antipollut & Saf Res Center 燃料タンク内蔵式燃料ポンプ
JPS6072975U (ja) * 1983-10-26 1985-05-22 ヤンマーディーゼル株式会社 燃料ポンプのエア抜き装置
JPH0621066B2 (ja) * 1984-03-14 1994-03-23 杏林製薬株式会社 ３―イソブチリル―２―イソプロピルピラゾロ〔１，５―ａ〕ピリジンの徐放性医薬品組成物
US4925849A (en) * 1987-06-15 1990-05-15 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutically useful pyrazolopyridines
JPH085790B2 (ja) * 1988-11-11 1996-01-24 杏林製薬株式会社 記憶障害改善薬
JPH0256853U (fr) * 1989-10-04 1990-04-24
JPH06166687A (ja) * 1990-07-18 1994-06-14 Senju Pharmaceut Co Ltd ピラゾロ〔１，５−ａ〕ピリジン化合物、その製造法および用途
CA2715683A1 (fr) 1999-08-21 2001-03-01 Nycomed Gmbh Combinaison synergiste
CN1681495B (zh) 2002-08-19 2010-05-12 辉瑞产品公司 用于治疗过度增生性疾病的组合物
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
AU2004226353A1 (en) 2003-04-01 2004-10-14 Laboratoires Serono Sa Inhibitors of phosphodiesterases in infertility
WO2004106299A2 (fr) 2003-05-30 2004-12-09 Ranbaxy Laboratories Limited Derives pyrroliques substitues
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
ZA200604253B (en) 2003-11-21 2007-10-31 Combinatorx Inc Methods and reagents for the treatment of inflammatory disorders
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
KR101329112B1 (ko) 2005-11-08 2013-11-14 랜박시 래보러터리스 리미티드 (3ｒ,5ｒ)-7-〔2-(4-플루오로페닐)-5-이소프로필-3-페닐-4-〔(4-히드록시 메틸 페닐 아미노)카르보닐〕-피롤-1-일〕-3,5-디히드록시 헵탄산 헤미 칼슘염의 제조 방법
CA2628570A1 (fr) 2005-11-09 2007-05-18 Combinatorx, Incorporated Procedes, compositions et kits pour le traitement de pathologies
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
JP5352452B2 (ja) * 2006-06-06 2013-11-27 メディシノバ， インコーポレイテッド 置換ピラゾロ［１，５−ａ］ピリジン化合物およびその使用方法
CN101663262B (zh) 2006-12-01 2014-03-26 百时美施贵宝公司 用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物
PL2131841T3 (pl) 2007-01-30 2013-03-29 Avigen Inc Sposoby leczenia bólu ostrego
ES2393885T7 (es) 2007-06-04 2014-01-30 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US7536799B2 (en) * 2007-06-07 2009-05-26 Keson Industries Chalk line apparatus with strategically located chalk fill opening
AU2008273050A1 (en) * 2007-07-11 2009-01-15 Auckland Uniservices Limited Pyrazolo[1,5-a]pyridines and their use in cancer therapy
AU2008287421A1 (en) * 2007-08-10 2009-02-19 Glaxosmithkline Llc Nitrogen containing bicyclic chemical entities for treating viral infections
CA2696041A1 (fr) * 2007-08-15 2009-02-19 Kyorin Pharmaceutical Co., Ltd. Agent preventif, inhibiteur ou remede pour l'anevrisme cerebral comportant de l'ibudilast en tant qu'ingredient actif
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
WO2010005520A2 (fr) * 2008-06-30 2010-01-14 Concert Pharmaceuticals, Inc. Dérivés de 2-alkyl-3-acylpyrazolo[1,5-a]pyridines
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
JP2011530511A (ja) * 2008-08-05 2011-12-22 メルク・シャープ・エンド・ドーム・コーポレイション 治療用化合物
WO2010021681A2 (fr) * 2008-08-18 2010-02-25 Combinatorx (Singapore) Pte. Ltd. Compositions et procédés pour le traitement de maladies virales
WO2011059053A1 (fr) 2009-11-13 2011-05-19 東レ株式会社 Agent de traitement ou de prévention du diabète
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
JP6251038B2 (ja) 2011-03-01 2017-12-20 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃアゴニストの調製方法
ES2395801B1 (es) 2011-06-23 2014-06-06 María Carmen PARDINA PALLEJÀ "pentoxifilina por vía transvaginal para el tratamiento de la infertilidad"
CN102617579A (zh) * 2012-03-28 2012-08-01 黑龙江大学 一种异丁司特的制备方法
AU2014218599C1 (en) 2013-02-25 2018-09-06 Bausch Health Ireland Limited Guanylate cyclase receptor agonists for use in colonic cleansing
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
CA2905435A1 (fr) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions utiles pour le traitement de troubles gastro-intestinaux
WO2014170786A1 (fr) 2013-04-17 2014-10-23 Pfizer Inc. Dérivés de n-pipéridin-3-ylbenzamide dans le traitement des maladies cardiovasculaires
US10011637B2 (en) 2013-06-05 2018-07-03 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase C, method of making and using same
JP6694385B2 (ja) 2013-08-09 2020-05-13 アーデリクス，インコーポレーテッド リン酸塩輸送阻害のための化合物及び方法
WO2016055901A1 (fr) 2014-10-08 2016-04-14 Pfizer Inc. Composés d'amide substitué
CN108033959A (zh) * 2018-01-29 2018-05-15 山东省药学科学院 一种异丁司特的化学合成方法
CN113574055A (zh) 2019-01-18 2021-10-29 阿斯利康(瑞典)有限公司 Pcsk9抑制剂及其使用方法
JP2022533251A (ja) 2019-05-21 2022-07-21 アルデリックス， インコーポレイテッド 患者において血清リン酸塩を低下させるための組み合わせ
CN113387947B (zh) * 2021-07-12 2022-07-01 中国科学院成都生物研究所 调节雌激素受体合成活性的吡唑并吡啶衍生物

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2289192A1 (fr) * 1974-11-01 1976-05-28 Kyorin Seiyaku Kk Pyrazolo(1,5-a)pyridines et medicament contenant ces substances
EP0215438A2 (fr) * 1985-09-14 1987-03-25 Kyorin Seiyaku Kabushiki Kaisha Utilisation de la 3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine pour préparer un médicament antirhumatismal
EP0215438A3 (en) * 1985-09-14 1989-05-24 Kyorin Seiyaku Kabushiki Kaisha Use of 3-isobutyryl-2-isopropylpyrazoloû1,5-a¨pyridine as an anti-rheumatic agent
EP0319902A3 (en) * 1987-12-10 1990-01-31 Kyorin Seiyaku Kabushiki Kaisha Transdermal absorptive drug formulation
US5602165A (en) * 1987-12-10 1997-02-11 Kyorin Seiyaku Kabushiki Kaisha Transdermal absorptive drug formulation
EP0355234A1 (fr) * 1988-08-25 1990-02-28 Merrell Dow Pharmaceuticals Inc. Dérivés de la pyrazolo-pyridine avec activité antiethérosclérotique et hypecholesthérolémique

Also Published As

Publication number Publication date
CA989843A (en) 1976-05-25
FR2182914B1 (fr) 1976-05-14
US3850941A (en) 1974-11-26
HU167305B (fr) 1975-09-27
GB1378375A (en) 1974-12-27
AU5376173A (en) 1974-09-26
DE2315801B2 (de) 1978-06-22
JPS5229318B2 (fr) 1977-08-01
AR197709A1 (es) 1974-04-30
BR7302268D0 (pt) 1974-08-29
BE797554A (fr) 1973-07-16
DE2315801A1 (de) 1973-10-11
SE402592B (sv) 1978-07-10
DE2315801C3 (de) 1979-02-22
JPS4897898A (fr) 1973-12-13
ES413188A1 (es) 1976-01-16

Similar Documents

Publication Publication Date Title
FR2182914B1 (fr)
JPS4949315A (fr)
FR2212255A1 (fr)
FR2175079B1 (fr)
FR2189827A1 (fr)
JPS499506A (fr)
JPS4947664A (fr)
JPS5230489Y2 (fr)
JPS5111622B2 (fr)
JPS4886261U (fr)
JPS48101602A (fr)
JPS5240020Y2 (fr)
JPS4934476A (fr)
JPS4992975A (fr)
CH586263A5 (fr)
CH575901A5 (fr)
CH573358A5 (fr)
BG18396A1 (fr)
BG18715A1 (fr)
NL7302722A (fr)
CH585260A5 (fr)
CH573787A5 (fr)
BG18093A1 (fr)
BG20310A3 (fr)
BG18040A1 (fr)